Nucleai Company Profile

Background

Overview

Nucleai is an AI-powered spatial biology company founded in 2017, specializing in transforming drug development and clinical treatment decisions by unlocking the power of pathology data. The company provides pharmaceutical companies, contract research organizations (CROs), and diagnostic laboratories with a state-of-the-art AI platform to enhance clinical trials and clinical decision-making.

Mission and Vision

Nucleai's mission is to revolutionize precision medicine by integrating spatial biology into clinical practice, enabling more informed treatment decisions and accelerating the development of novel therapies. The company's vision is to embed the use of its platform in every clinical trial involving tissue, thereby improving patient outcomes and advancing the field of oncology.

Primary Area of Focus

The company's primary focus is on spatial biology, utilizing AI to analyze tissue samples and map cellular interactions. This approach aims to predict therapeutic outcomes, identify novel biomarkers, and support the development of precision therapies, particularly in oncology.

Industry Significance

Nucleai plays a pivotal role in the biotechnology and healthcare industries by bridging the gap between pathology data and actionable clinical insights. Its innovative platform enhances the efficiency of drug development processes and improves the precision of clinical treatments, contributing to the advancement of personalized medicine.

Key Strategic Focus

Core Objectives

Advancement of Spatial Biology: Integrate spatial biology into clinical practice to enable more precise treatment decisions.

Enhancement of Drug Development: Accelerate the discovery and validation of biomarkers to improve the efficacy of clinical trials.

Personalized Medicine: Utilize AI to tailor therapies to individual patients, optimizing treatment outcomes.

Specific Areas of Specialization

AI-Powered Spatial Analysis: Employ artificial intelligence to analyze complex tissue samples, mapping cellular interactions and spatial relationships.

Biomarker Discovery: Identify and validate novel biomarkers that can predict patient responses to therapies.

Clinical Decision Support: Provide tools that assist clinicians in making informed treatment decisions based on comprehensive tissue analysis.

Key Technologies Utilized

Deep Learning Models: Develop and deploy deep learning algorithms to process and interpret high-dimensional spatial data.

Multiplex Imaging: Utilize advanced imaging techniques to capture detailed spatial information from tissue samples.

AI-Driven Biomarker Scoring: Implement AI models to score and interpret biomarkers, facilitating their use in clinical settings.

Primary Markets Targeted

Biopharmaceutical Companies: Collaborate to enhance drug development processes and improve clinical trial outcomes.

Contract Research Organizations (CROs): Partner to provide advanced analytical tools for clinical research.

Diagnostic Laboratories: Offer solutions to improve diagnostic accuracy and support personalized treatment plans.

Financials and Funding

Funding History

Since its inception, Nucleai has secured significant funding to support its growth and technological advancements.

Total Funds Raised

The company has raised a total of approximately $60 million across multiple funding rounds.

Recent Funding Rounds

Series B Financing (March 2022): Raised $33 million, led by Section 32 and Sanofi Ventures, with participation from existing investors.

Investment from M Ventures (April 2024): Secured $14 million from M Ventures, the corporate venture capital arm of Merck KGaA, Darmstadt, Germany.

Notable Investors

Section 32: A venture capital firm investing at the frontiers of technology and healthcare.

Sanofi Ventures: The corporate venture capital arm of Sanofi, focusing on early-stage biotech and digital health companies.

M Ventures: The corporate venture capital arm of Merck KGaA, Darmstadt, Germany, investing in innovative life sciences companies.

Intended Utilization of Capital

The funds are allocated to further develop Nucleai's AI-powered spatial biology platform, expand its commercial footprint across biopharmaceutical companies and CROs, and enhance the deployment of its technology in clinical trials and diagnostic applications.

Pipeline Development

Key Pipeline Candidates

Nucleai's pipeline focuses on the development of AI-driven spatial biomarkers and diagnostic tools to support precision medicine.

Stages of Clinical Trials or Product Development

Clinical Trials: The company is actively involved in clinical trials, utilizing its platform to aid in patient stratification and biomarker discovery.

Diagnostic Applications: Developing diagnostic tools that integrate spatial biology insights to improve clinical decision-making.

Target Conditions

Oncological Indications: Particularly focusing on cancers such as non-small cell lung cancer (NSCLC) and melanoma.

Immuno-Oncology: Developing biomarkers to predict patient responses to immunotherapies.

Relevant Timelines for Anticipated Milestones

Clinical Trial Support: Ongoing collaborations with biopharmaceutical companies to integrate spatial biomarkers into clinical trials.

Diagnostic Tool Deployment: Plans to launch AI-powered diagnostic tools in collaboration with diagnostic laboratories.

Technological Platform and Innovation

Proprietary Technologies

ATOM Platform: Nucleai's proprietary AI platform that analyzes tissue samples to map cellular interactions and predict therapeutic outcomes.

Significant Scientific Methods

Deep Learning Algorithms: Utilized to process and interpret complex spatial data from tissue samples.

Multiplex Imaging Techniques: Employed to capture detailed spatial information, enabling high-dimensional analysis of tissue samples.

AI-Driven Capabilities

Spatial Biomarker Discovery: Leveraging AI to identify and validate novel biomarkers that can predict patient responses to therapies.

Clinical Decision Support: Providing AI-driven insights to assist clinicians in making informed treatment decisions based on comprehensive tissue analysis.

Leadership Team

Key Executives

Avi Veidman: Chief Executive Officer (CEO). Avi has been leading Nucleai since its inception, driving the company's vision and strategic direction.

Oscar Puig, Ph.D.: Vice President of Translational Medicine & Diagnostics. Dr. Puig brings extensive experience in oncology research and development, contributing to Nucleai's scientific advancements.

Suzana Couto: Scientific Advisor. As the Head of Pathology at Neomorph Inc, Suzana provides strategic guidance on pathology-related initiatives.

Leadership Changes

Dr. Julian Adams: Joined Nucleai's Scientific Advisory Board, bringing over 35 years of experience in oncology research and development.

Competitor Profile

Market Insights and Dynamics

The spatial biology and AI-driven diagnostics market is rapidly evolving, with increasing demand for precision medicine solutions. The integration of AI into pathology is transforming drug development and clinical decision-making processes.

Competitor Analysis

PathAI: A leading competitor specializing in AI-powered pathology diagnostics, focusing on improving accuracy and efficiency in pathology.

Reveal Biosciences: Competes in the healthcare equipment and services sector, offering pathology services with a focus on tissue analysis.

Idoven: Operates within the healthcare technology sector, providing AI solutions for medical diagnostics.

Strategic Collaborations and Partnerships

Mayo Clinic BioPharma Diagnostics: Announced a strategic collaboration to integrate Nucleai's AI-powered spatial biology technology with Mayo Clinic's data and lab services.

Lunaphore: Partnered to provide AI-powered spatial biology analysis, combining Lunaphore's COMET™ platform with Nucleai's ATOM platform.

Propath UK: Collaborated to develop a 30-plex immunofluorescence panel and associated AI-powered algorithm for biomarker discovery.

Operational Insights

Nucleai's strategic collaborations enhance its technological capabilities and expand its market reach, positioning the company as a leader in AI-driven spatial biology solutions.

nucleai